Gemfibrozil: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antihyperlipidemic *Dosage Forms: *Routes of Administration: oral *Common Trade Names: ==Adult Dosing== *600mg PO BID 30m before meals ==Pediatric...") |
No edit summary |
||
| Line 3: | Line 3: | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: oral | *Routes of Administration: oral | ||
*Common Trade Names: | *Common Trade Names: Lopid | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 9: | Line 9: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established'' | *''Safety/efficacy not established'' | ||
==Special Populations== | ==Special Populations== | ||
Revision as of 07:46, 1 September 2017
Administration
- Type: Antihyperlipidemic
- Dosage Forms:
- Routes of Administration: oral
- Common Trade Names: Lopid
Adult Dosing
- 600mg PO BID 30m before meals
Pediatric Dosing
- Safety/efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: not recommended in severe renal impairment
- Hepatic dosing: contraindicated in hepatic dysfunction
Contraindications
- Allergy to class/drug
- Concomitant dasabuvir, repaglinide, or simvastatin
- Hepatic dysfunction, primary biliary cirrhosis, preexisting gallbladder disease
- Severe renal impairment
Adverse Reactions
Serious
- Increased LFTs
- Rhabdomyolysis
Common
- Abdominal pain, indigestion
- Appendicitis
Pharmacology
- Half-life: 1.5h
- Metabolism: Hepatic. Inhibitor of CYP2C8, OATP1B1, and OAT3, substrate of UGT2B7
- Excretion: Mostly renal
Mechanism of Action
- Stimulates peroxisome proliferator activated receptor alpha, which causes a decrease in triglyceride levels and an increase in high-density lipoprotein levels